Company Overview and News

0
Bet on these top 3 stocks which are likely to benefit the most from GST

2018-06-30 moneycontrol
Goods and Services Tax (GST) was one of the India’s most bold reforms. We have seen little hiccups in the execution, but it has come a long way.
532497 RADICO

0
Sebi initiates probe into alleged leak of list of cos under enhanced surveillance measures

2018-06-06 moneycontrol
Markets regulator Sebi today said it has initiated a probe into alleged leak of 37 companies being brought under enhanced surveillance before stock exchanges made the list public.
RAIN 532497 500339 RADICO

0
List of stocks on SEBI’s ‘monitor list’ was leaked, suspect traders

2018-06-05 thehindubusinessline
Was a list of stocks that were to be included in Additional Surveillance Measure (ASM), the new category formed by SEBI to check market manipulation, leaked to operators ahead of its official release? A section of stock market brokers and top traders suspect that operators in Mumbai and Gujarat may have had access to the list on May 31 before it was officially put up on stock exchange websites.
517421 ALNSE 500339 513269 MANINDS 533333 RAIN 532497 FCL RADICO BUTTERFLY EXCELINDUS 500650

0
Radico Khaitan Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532497 RADICO

0
Top 12 stocks to invest ahead of May FO expiry which could give up to 6-20% return

2018-05-28 moneycontrol
The Nifty50 closed flat with a positive bias for the week ended May 25 above its crucial resistance level of 10,600. It was indeed a roller coaster rise for Nifty which rebounded nearly 200 points after hitting a low of 10,417 to close the week at 10,605 on Friday.
JUSTDIAL 532432 500408 532497 535648 KAJARIACER UNITDSPR UQNTY RADICO 500233 TATAELXSI JSTQY

62
Closing Bell: Sensex down 301 pts, Nifty below 10,600; ICICI Bank, LT, Tata Motors dip 3%

2018-05-18 moneycontrol
Market Closing: Benchmark indices ended sharply lower, continuing weakness for the fourth consecutive session amid uncertainty over government formation in Karnataka, likely fiscal imbalance due to higher crude oil prices and weaker rupee.
BAJAJ-AUTO 500008 BHUSANSTL HIMATSEIDE GLBRF ARJQY 511218 532482 UCLQY SRRQY BJJQY 500570 500055 SYNGENE GRAPHITE CLGQY JETAIRWAYS 539268 ULTRACEMCO JSWSTEEL BAJAJFINSV BAJFINANCE KOTAKBANK HINDPETRO 500104 GGGBY 500228 532617 KTKBANK 532978 532538 532977 533155 SRTRANSFIN JUBLFOOD AMARAJABAT GRANULES CL 533309 JBLWY RADICO TATAMOTORS 509488 500034 514043 DALMIABHA KMBKY IBN UCLQF 532652 532497 ICICIBANK 532174 500247 TTM

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...